Singtel, NUHS and Ericsson expand healthcare AI partnership

By James Calloway

On Nov. 3, 2026, Singapore operator Singtel, the National University Health System (NUHS) and network vendor Ericsson signed a memorandum of understanding to expand their healthcare technology partnership through a new research and development platform for connected care, artificial intelligence and next-generation mobile networks.

Under the agreement, Singtel and Ericsson become founding partners of the National University XG AI Centre, or NXAC, which NUHS established. The parties plan to start with 5G and 5G-Advanced capabilities before pursuing a longer-term path toward early 6G.

The memorandum disclosed no investment amount, earnings forecast or commercial timetable.

What will NXAC test?

NUHS established NXAC to move emerging connectivity and AI work from research into practical healthcare applications and test it in a working hospital environment. Singtel, Ericsson and NUHS plan to work with clinicians, nurses and hospital operations teams, rather than assess the technology in isolation.

The stated areas of work include:

• Ambient AI for clinical workflows and spatial intelligence.
• Connected medical devices, wearables and hospital-at-home services.
• Autonomous robotics and digital twins.
• Medical extended reality.

Ericsson separately identified remote monitoring, robotic surgery and clinical collaboration as applications for which it would contribute research and advanced network capabilities.

Where do 5G-Advanced and 6G fit?

The first phase depends on 5G and 5G-Advanced, while early 6G belongs to a longer-term research path. That sequence keeps initial work tied to the two 5G generations as partners explore a future generation.

The partnership announcement calls NXAC the world's first 6G AI centre dedicated to healthcare. That designation comes from the partners' own announcement, which attaches no revenue guidance or financial target to it. The wording also should not be read as evidence of a commercial early-6G network: no 6G coverage, deployment schedule or hospital trial timetable is disclosed.

What changes for hospitals and patients?

The immediate change is a route to test technologies with clinical staff in a live hospital environment. The parties plan to examine whether ambient tools, connected devices, remote care, robots, digital twins and extended reality become usable in clinical workflows. It is a research-to-deployment route, not yet a new healthcare service or a disclosed 6G rollout.

For patients, the announcement offers no immediate treatment, coverage or performance benefit because it gives no trial sites, launch dates or service metrics. The practical benefit will depend on whether research projects become deployable applications and customer contracts.

For hospital operators, the partnership offers a way to shape applications before deployment. The plan puts clinicians, nurses and operations teams inside the process, while joint training and fellowships will support the move from research into hospital trials.

What is the commercial angle for Singtel?

For Singtel, the initiative reinforces its strategy of combining telecommunications infrastructure with digital and AI services. Singtel Singapore CEO Ng Tian Chong said the company would “contribute network and digital capabilities” as Singapore addresses an ageing population and more complex healthcare needs.

Ericsson said its role would “include research and advanced network capabilities” for remote monitoring, robotic surgery and clinical collaboration. The three-way structure links Singtel's network and digital services with NUHS's hospital environment and clinical teams, and Ericsson's advanced-network research.

For investors, Singapore remains the relevant trading backdrop, with broader regional market reports providing wider stock context. Singtel carries the ISIN SG1T75931496, but the memorandum supplies no quantified share-price reaction, earnings forecast, revenue target or commercial timetable.

Further development depends on joint training, fellowships, research funding and trials in healthcare facilities. Until those steps produce deployable applications and customer contracts, neither an early-6G rollout nor any revenue contribution can be placed on a timetable.